BPC 157: What It Is, What We Know, and Why Its Use for Arthritis Remains Unproven San Diego Orthobiologics Medical Group Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 The Foundation of Cellular Repair and Recovery BPC 157, or Body Protection Compound 157, is a regenerative peptide known for supporting the body's natural healing process. Studied for its role in tissue FDA Issues Warning: Compounding Certain Bulk Drug Substances May Pose Major Legal and Patient Safety Risks Lengea In 2023, the FDA deemed 19 peptide drugs too unsafe to be dispensed by compounding pharmacies, which mix components of approved drugs to create bespoke medication for people who have trouble taking